Investigational Studies

On June 25th, 2018, the U.S. Food and Drug Administration (FDA) approved the drug, Epidiolex, for the treatment of seizures associated with two rare forms of epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome[1]. The active ingredient in Epidiolex, cannabidiol (CBD), is a chemical compound found in marijuana, but is not associated with the euphoria caused by […]

by

In recent years, we have seen some extraordinary results related to the use of CBD for treatment and therapy in a variety of different health conditions. However, there is one particular condition that perhaps sits atop the pyramid as far as the sense of dramatic relief related to CBD use:  Dravet Syndrome. Understanding Dravet Syndrome […]

by

In recent years, we have seen some extraordinary results related to the use of CBD for treatment and therapy in a variety of different health conditions. However, there is one particular condition that perhaps sits atop the pyramid as far as the sense of dramatic relief related to CBD use:  Dravet Syndrome. Understanding Dravet Syndrome […]

by

Opdivo, Yervoy Combination For Colorectal Cancer Cases The combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both made by Bristol-Myers Squibb, has received FDA accelerated approval for the treatment of adult and pediatric patients 12 years of age and older with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer (mCRC) that has progressed following […]

by

Opdivo, Yervoy Combination For Colorectal Cancer Cases The combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both made by Bristol-Myers Squibb, has received FDA accelerated approval for the treatment of adult and pediatric patients 12 years of age and older with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer (mCRC) that has progressed following […]

by

Opdivo, Yervoy Combination For Colorectal Cancer Cases The combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both made by Bristol-Myers Squibb, has received FDA accelerated approval for the treatment of adult and pediatric patients 12 years of age and older with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer (mCRC) that has progressed following […]

by

Zogenix, Inc.  announced successful completion of its second confirmatory phase III study (Study 1504) evaluating its pipeline candidate, ZX008 (low-dose fenfluramine hydrochloride), for treating Dravet syndrome, a type of epilepsy in children and young adults. The data was consistent with the positive results observed in the first pivotal phase III study in reducing monthly convulsive […]

The U.S. Food and Drug Administration on Monday approved the country’s first drug derived from marijuana, a medication that treats two rare and devastating forms of epilepsy. The drug, produced by GW Pharmaceuticals plc (Nasdaq: GWPH) and called Epidiolex®, is made from cannabidiol (CBD), a component of marijuana that does not give users a high. […]

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaqs use of your personal data can be found in our Privacy and Cookies Notice): To allow you to personalize the Mondaq websites you are visiting to show content (“Content”) relevant […]